跳至主要内容
临床试验/NCT00268216
NCT00268216已完成3 期

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment

GlaxoSmithKline459 个研究点 分布在 1 个国家目标入组 6,228 人开始时间: 2000年9月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
6,228
试验地点
459
主要终点
All cause mortality at 3 years

研究概览

简要总结

The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.

详细描述

A multicenter, randomized, double-blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the DISKUS/ACCUHALER inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

All cause mortality at 3 years

次要结局

  • Rate of moderate and severe COPD exacerbations and health status assessed by the St. George's Respiratory Questionnaire.

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (459)

Loading locations...

相似试验